Impact of the US Patent System on the Promise of Personalized Medicine

2004, Finishing the euchromatic sequence of the human genome, Nature, 431, 931, 10.1038/nature03001 Tachikawa, 2006, Targeting the human genome, Curr Opin Biotechnol, 17, 659, 10.1016/j.copbio.2006.10.010 Antoniou, 2003, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies [published correction appears in Am J Hum Genet. 2003;73:709], Am J Hum Genet, 72, 1117, 10.1086/375033 National Human Genome Research Institute. An open access on-line breast cancer mutation data base. Available at: http://research.nhgri.nih.gov/bic/. 1997, A simple genetic test identifies 90% of UK patients with haemochromatosis, Gut, 41, 841, 10.1136/gut.41.6.841 Dorak, 1999, The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia, Blood, 94, 3957, 10.1182/blood.V94.11.3957 US Const, art I, §8. 35 USC, §101-103. 35 USC, §101. 1980, Diamond v Chakrabarty Jensen, 2005, Intellectual property landscape of the human genome, Science, 310, 239, 10.1126/science.1120014 United States Patent and Trademark Office. Issued patents. Available at: http://www.uspto.gov/patft/index.html. 1980, Diamond v Chakrabarty Von Der Ropp, 2006, Bioethics and patent law: The case of Myriad, WIPO Magazine, 4, 8 2002, The ethics of patenting DNA: Discussion paper 2005, Merck KgaA v Integra Lifesciences I, Ltd 1990, Eli Lilly & Co v Medtronic, Inc 110th Cong, 1st Sess, S 1145, HR 1908, introduced April 18, 2007. Becerra, 2007, bill to ban the practice of gene patenting